Authors: | Cohen, N. A.; Strong, V. E.; Janjigian, Y. Y. |
Article Title: | Checkpoint blockade in esophagogastric cancer |
Abstract: | There are few effective treatment options for metastatic esophagogastric adenocarcinomas after progression on second-line chemotherapy. Immune checkpoint blockade therapy is a promising treatment strategy for selected advanced esophagogastric cancer, and the PD-1 inhibitor pembrolizumab has recently been approved for metastatic or recurrent gastric or gastroesophageal junction cancer that has progressed beyond second-line systemic therapy. We review the current data supporting immune checkpoint blockade therapy in advanced esophagogastric adenocarcinoma. © 2018 Wiley Periodicals, Inc. |
Keywords: | protein expression; treatment response; review; advanced cancer; drug efficacy; antineoplastic agent; adenocarcinoma; cancer immunotherapy; randomized controlled trials as topic; pathology; monoclonal antibody; immunology; antibodies, monoclonal; immunotherapy; stomach cancer; cytotoxic t lymphocyte antigen 4; esophagus cancer; stomach neoplasms; gastroesophageal; stomach tumor; pd-1; esophagogastric junction; programmed death 1 ligand 1; programmed death 1 receptor; randomized controlled trial (topic); gastric; gastroesophageal junction; ctla-4 antigen; nivolumab; humans; human; priority journal; checkpoint inhibitor; antagonists and inhibitors; pdcd1 protein, human; programmed cell death 1 receptor; cd274 protein, human; b7-h1 antigen; ctla4 protein, human |
Journal Title: | Journal of Surgical Oncology |
Volume: | 118 |
Issue: | 1 |
ISSN: | 0022-4790 |
Publisher: | Wiley Blackwell |
Date Published: | 2018-07-01 |
Start Page: | 77 |
End Page: | 85 |
Language: | English |
DOI: | 10.1002/jso.25116 |
PUBMED: | 29878357 |
PROVIDER: | scopus |
PMCID: | PMC7891842 |
DOI/URL: | |
Notes: | Review -- Export Date: 1 October 2018 -- Source: Scopus |